文献速递眼底病与葡萄膜炎青光眼白内障与屈光手术

非诺贝特使用与糖尿病患者眼部疾病进展的关联

Association of fenofibrate use with progression of ocular disease in individuals with diabetes.
PubMed 文献 · Br J Ophthalmol · 2026-08-21

本研究利用TriNetX国际数据库开展回顾性队列研究,纳入≥18岁糖尿病合并轻中度非增殖性糖尿病视网膜病变(NPDR)患者,比较使用与不使用非诺贝特者进展为视力威胁性DR(VTDR)、白内障、原发性开角型青光眼(POAG)或糖尿病黄斑水肿(DME)的风险。经倾向性评分匹配后,非诺贝特使用与VTDR、白内障和DME风险显著降低相关。

要点

  • 非诺贝特使用与VTDR进展风险降低相关(OR 0.528,95%CI 0.333-0.838;p=0.0059)。
  • 非诺贝特使用与白内障风险降低相关(OR 0.585,95%CI 0.441-0.774;p=0.0002)。
  • 非诺贝特使用与DME风险降低相关(OR 0.316,95%CI 0.243-0.411;p<0.0001)。

核心结论

  • 在轻中度NPDR糖尿病患者中,非诺贝特使用与VTDR、白内障和DME风险显著降低相关。

研究设计与样本

  • 经倾向性评分匹配后,分别有4316、4200、4073和4571名使用非诺贝特者与等量未使用者比较VTDR、白内障、POAG和DME结局。

主要发现

  • 非诺贝特使用组进展为VTDR的OR为0.528(95%CI 0.333-0.838;p=0.0059)。
  • 非诺贝特使用组发生白内障的OR为0.585(95%CI 0.441-0.774;p=0.0002)。
  • 非诺贝特使用组发生DME的OR为0.316(95%CI 0.243-0.411;p<0.0001)。

临床怎么用

  • 对于糖尿病合并轻中度NPDR的患者,非诺贝特使用可能与降低VTDR、白内障和DME风险相关,临床决策时可综合考虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: Fenofibrates may slow progression of diabetic retinopathy (DR). This study used the large international TriNetX database to evaluate progression of retinopathy and development of cataracts, primary open angle glaucoma (POAG) and diabetic macular oedema (DME) in patients with diabetes with and without fenofibrate use. METHODS: In this retrospective cohort study, ICD10 codes and RxNorm were used to identify patients in the TriNetX database aged ≥18 years with a diagnosis of diabetes mellitus (DM), with mild or moderate non-proliferative diabetic retinopathy (NPDR) and with and without fenofibrate use from December 2014 through December 2024. ORs were calculated to analyse the proportion of individuals with mild or moderate NPDR using fenofibrate who developed vision-threatening DR (VTDR, defined as severe NPDR or proliferative DR), cataracts, POAG or DME compared with those not taking fenofibrate. Those with cataracts, POAG or DME at baseline were excluded from their respective outcomes analyses. RESULTS: After propensity score matching, 4316, 4200, 4073 and 4571 individuals prescribed fenofibrate were compared with the same number who were not prescribed fenofibrate for progression to VTDR, cataract, POAG or DME, respectively. The ORs for DR progression (OR 0.528, 95% CI 0.333 to 0.838; p=0.0059), cataract (OR 0.585, 95% CI 0.441 to 0.774; p=0.0002) and DME (OR 0.316, 95% CI 0.243 to 0.411; p<0.0001) development were lower for individuals taking fenofibrate compared with those not taking fenofibrate. CONCLUSION: Fenofibrate use is associated with significantly lower risk of developing VTDR, cataracts and DME in patients with mild or moderate NPDR.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Oliver C, Berkenstock MK, Sachdeva MM, et al. Association of fenofibrate use with progression of ocular disease in individuals with diabetes. Br J Ophthalmol. 2026. PMID: 42629173. doi:10.1136/bjo-2026-329642

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。